NIPER Mohali and Novartis Partner to Accelerate Pharma Innovation and Academic Research

Emphasizing the importance of translating academic research into tangible outcomes, Shri Manoj Joshi highlighted the need for deeper and more structured collaboration between institutions and industry players.

In a major push to strengthen India’s pharmaceutical innovation ecosystem, the National Institute of Pharmaceutical Education and Research (NIPER), Mohali has entered into a landmark collaboration with Novartis Healthcare Private Limited (NHPL). The agreement, signed in New Delhi, marks a significant step toward bridging the gap between academic research and industry application, with a strong focus on advancing cutting-edge healthcare solutions.

The signing ceremony was held in the presence of Shri Manoj Joshi, Secretary, Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers, along with senior government officials, academic leaders, and top executives from Novartis India—underscoring the strategic importance of the partnership.

Driving Industry-Academia Synergy in Pharmaceutical Research

At the core of the collaboration lies a shared vision to foster meaningful engagement between academia and industry, ensuring that research outcomes are not only innovative but also aligned with real-world healthcare and market needs.

A key highlight of the initiative is the Development Pioneer Grant for NIPERs, a prestigious programme supported by Novartis. Designed to encourage high-impact research and innovation, the grant provides a competitive platform for faculty members across all seven NIPER institutions to submit advanced Research & Development proposals.

The response to the programme has been notably strong, with 42 research proposals submitted by distinguished faculty members nationwide—reflecting both the depth of academic talent and the growing interest in industry-linked research. Following a rigorous, multi-stage evaluation process conducted by an independent expert jury, a faculty member from NIPER Mohali was selected as the grant recipient.

From Research to Real-World Impact

Emphasizing the importance of translating academic research into tangible outcomes, Shri Manoj Joshi highlighted the need for deeper and more structured collaboration between institutions and industry players.

“This is a commendable initiative. Expanding such collaborations will significantly enhance the relevance and impact of research by aligning it with industry requirements. We must move beyond pilot stages and ensure that research outputs are scalable, applicable, and contribute meaningfully to the pharmaceutical sector,” he stated.

His remarks reflect a broader policy shift within the Department of Pharmaceuticals toward outcome-oriented research, where innovation is closely tied to commercialization potential, regulatory readiness, and patient impact.

Strengthening India’s Pharmaceutical Innovation Ecosystem

The Development Pioneer Grant aligns with the Government of India’s vision to build a robust, innovation-driven pharmaceutical sector capable of competing globally. By supporting advanced research and fostering partnerships with leading global companies like Novartis, the initiative aims to:

• Enhance the research capabilities of academic institutions

• Promote translational research and technology transfer

• Encourage co-development of innovative therapies and solutions

• Strengthen India’s position as a global hub for pharmaceutical R&D

This collaboration is expected to integrate NIPER more deeply into the global pharmaceutical innovation network, opening avenues for knowledge exchange, capacity building, and access to cutting-edge technologies.

Industry Leadership and Academic Excellence Come Together

The agreement also highlights Novartis’ continued commitment to supporting scientific research and innovation in India. By investing in academic partnerships, the company aims to nurture talent, accelerate discovery, and contribute to the development of next-generation healthcare solutions.

The signing ceremony was attended by key stakeholders including Shri Awadhesh Kumar Choudhary, Senior Economic Advisor, Department of Pharmaceuticals; Dr. Kinny Singh, Deputy Secretary; Prof. Dulal Panda, Director of NIPER Mohali; Prof. Joydev Kumar Laha; Mr. Amitabh Dube, Country President India, Novartis; and Ms. Sadhna Joglekar, Head Development India, Novartis.

Their presence highlighted the collaborative spirit driving the initiative and the shared commitment to advancing scientific excellence in India’s pharmaceutical sector.

A Step Toward Future-Ready Healthcare Innovation

As India continues to expand its footprint in global pharmaceuticals—already accounting for nearly 20% of global generic drug supply—initiatives like this are critical in moving up the value chain toward innovation-led growth.

By fostering stronger academia-industry linkages and supporting high-quality research, the NIPER-Novartis partnership is poised to play a transformative role in shaping the future of healthcare innovation in India—ensuring that scientific breakthroughs translate into accessible, effective, and affordable treatments.